HRSA-22-033: Ryan White HIV/AIDS Program HIV Care Grant Program – Part B States/Territories Formula and AIDS Drug Assistance Program Formula and ADAP Supplemental Awards
Closed
This grant is closed. A newer notice from the same program is forecast: HIV Care Grant Program - Part B States/Territories Formula and AIDS Drug Assistance Program Formula and AIDS Drug Assistance Program Supplemental Awards: Pacific Islands Jurisdictions (HRSA-27-064). Status: Expected deadline December 31, 2026. It is in our archive of Health Resources and Services Administration notices from 2021.
Health Resources and Services Administration offered grants to state and local governments. It expected to make about 59 awards worth $1.3 billion in total. Applications closed on November 8, 2021.
From the official notice on Grants.gov, last changed July 23, 2021. Checked November 7, 2026.
- Total funding$1.3 billion
- Expected awards59
- Cost sharingNot required
- Funding typeGrant
Key dates
| Posted | July 23, 2021 |
|---|---|
| Deadline | November 8, 2021 |
| Archived by Grants.gov | January 7, 2022 |
Who can apply
This opportunity was open to state and local governments.
- State governments
Is this a realistic fit?
- No cost sharing or match is required.
What the grant funds
This notice announces the opportunity to apply for funding under the Ryan White HIV/AIDS Program (RWHAP) Part B Base, AIDS Drug Assistance Program (ADAP) Base, ADAP Supplemental, Minority AIDS Initiative (MAI), and Emerging Communities (EC) program. The purpose of this program is to assist states and territories in developing and/or enhancing access to a comprehensive continuum of high quality HIV care and treatment for low-income people with HIV. For the purposes of this program, “states/territories” include the 50 states, the District of Columbia, the Commonwealth of Puerto Rico, the Northern Mariana Islands, American Samoa, Guam, the U.S. Virgin Islands, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau.
Who has won HIV Care Formula Grants grants before
From fiscal 2021 to 2025, HIV Care Formula Grants (93.917) awarded $6.3 billion across 133 grant awards, an average of $47.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| California Department of Public Health | California | 3 | $742 million |
| Health Research, Inc. | New York | 2 | $663 million |
| Florida Department of Health | Florida | 3 | $643 million |
| Department of State Health Services | Texas | 3 | $636 million |
| State of Georgia Department of Public Health | Georgia | 3 | $369 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, HRSA-27-064, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is HRSA-22-033 still open?
No. It closed on November 8, 2021. A newer notice is forecast: HRSA-27-064, expected deadline December 31, 2026.
Who can apply for Ryan White HIV/AIDS Program HIV Care Grant Program – Part B States/Territories Formula and AIDS Drug Assistance Program Formula and ADAP Supplemental Awards?
Health Resources and Services Administration accepted applications from state and local governments.
What is the deadline for Ryan White HIV/AIDS Program HIV Care Grant Program – Part B States/Territories Formula and AIDS Drug Assistance Program Formula and ADAP Supplemental Awards?
Closed November 8, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $1.3 billion in total across about 59 awards.
Who has won HIV Care Formula Grants grants before?
The largest recipients over five fiscal years were California Department of Public Health, Health Research, Inc., Florida Department of Health. The program made 133 awards worth $6.3 billion in that time.
Similar open grants
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)
- Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required)